Barriers to HCP adoption of new indication
service:
qualitative interviews
CHALLENGE: A pharmaceutical company was launching a new indication in abdominal cancer. While patients needed better options post-metastasis, the treatment landscape had grown complex. Oncologists were already navigating multiple biomarkers, an established first-line standard, and recent additions to the armamentarium. How would they respond to another new agent?
INSIGHT: A pharmaceutical company was launching a new indication in abdominal cancer. While patients needed better options post-metastasis, the treatment landscape had grown complex. Oncologists were already navigating multiple biomarkers, an established first-line standard, and recent additions to the armamentarium. How would they respond to another new agent?
SOLUTION: A pharmaceutical company was launching a new indication in abdominal cancer. While patients needed better options post-metastasis, the treatment landscape had grown complex. Oncologists were already navigating multiple biomarkers, an established first-line standard, and recent additions to the armamentarium. How would they respond to another new agent?